Psilocybin research in the cancer field once centred on easing anxiety and depression linked to a diagnosis. It has now taken an interesting new turn by showing promise against a physical side effect of treatment itself.
A study published on Sept. 3 in the journal Science found that the compound can prevent nerve damage from chemotherapy in rodent tests. The work came from a team at the University of Texas MD Anderson Cancer Center. Neuropathic pain scholar Mario Heles helped lead the effort along with Moran Amit, a surgical oncologist and professor of head and neck surgery, and pain medicine professor Patrick Dougherty.
They gave mice two doses of psilocybin before chemotherapy drugs that often harm nerves. The treatment stopped the usual rise in pain sensitivity, protected the fine nerve endings in the skin and kept normal touch sensation intact. It worked against both platinum-based and taxane (plant-derived) drugs. Importantly, the mice still responded well to the cancer treatment, with no slowdown in tumour shrinkage and no change in immune signals.
The same protective signs appeared in tests on human nerve tissue taken from patients. In the study, researchers also looked at nerves removed during surgery and at lab-grown human nerve cells. They found that psilocybin kept the energy supply moving properly so the nerve endings stayed healthy.
Read more: New Zealand begins prescribing MDMA for severe PTSD treatment
Dosing merits more attention than the mushroom
What stands out most is the limited amount needed for long-lasting cover. Just two doses before chemotherapy protected the animals through six full treatment cycles. That protection held for the entire eight-month length of the study.
Researchers rarely see such durable results from so few doses in these models. If the pattern translates to people, a short preparatory course of medical psilocybin could shield patients across months of repeated chemotherapy sessions.
This possibility has received little attention, but it points to a practical way to guard against cumulative nerve harm without the need for daily dosing or repeated interventions such as cryotherapy (cold) during every chemotherapy session.
“Notably, psilocybin also preserved its protective efficacy in tumour-bearing mice, without measurable changes in tumour growth, positioning it as a safe candidate with true prophylactic [protective] potential against chemotherapy-induced peripheral neuropathy,” the authors explained in Science.
Potentially enabling patients to finish treatment
Nerve damage from chemotherapy, known as peripheral neuropathy, affects as many as 60 to 75 per cent of patients who receive certain drugs. It causes pain, numbness, tingling and heightened sensitivity to cold. It also ranks among the most common reasons people reduce doses or stop treatment early.
Many survivors still live with the symptoms years later. In the future, medical psilocybin could potentially help more patients complete their full planned regimens. Finishing those courses often leads to stronger cancer control and better long-term results.
This research has clear limits. All the main findings come from mice and lab work on human tissue, not from people receiving treatment. Human trials are only expected to begin later this year, so it remains unknown whether the same protection will appear in patients or how the compound will interact with chemotherapy in actual clinical settings.
An unexpected finding from @ScienceMagazine *
Psilocybin, the psychedelic compound found in certain mushrooms, may help prevent chemotherapy-induced peripheral neuropathy.
Given before chemotherapy (as few as two doses), it protected sensory nerves in mice treated with… pic.twitter.com/9wpzjr324g
— ilyas sahin, MD (@ilyassahinMD) September 6, 2026
Read more: Indigenous wisdom comes to Spain at first World Ayahuasca Forum
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
